Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Michelle Long

Nurse Practitioner Edgewood, KY Nurse Practitioner

NPI 1699976431 CMS profile 10501596

1 Medical Village Dr, Edgewood, KY 41017

Open in the dashboard

General payments

$332

10 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michelle Long of Edgewood, KY is reported in the CMS Open Payments database as having received $332 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $127 3
2023 General $154 3
2021 General $51 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Long
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Long were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Long Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $51 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $154 $166 $54–$529 $160
2024 $127 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Tempus AI, Inc $98 1 payment
  2. Novo Nordisk Inc $81 6 payments
  3. GlaxoSmithKline, LLC. $74 1 payment
  4. Seattle Genetics, Inc. $65 1 payment
  5. AstraZeneca Pharmaceuticals LP $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $332 10 payments
Products named General payments · program years 2021–2024
  1. TIVDAK $65 1 payment
  2. RYBELSUS $37 3 payments
  3. Ozempic $37 3 payments
  4. FASENRA $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

178

Median for Nurse Practitioner: 389

Drug cost

$36,078

Median for Nurse Practitioner: $21,885

Branded share of claims

34.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 48 $33,125
Megestrol Acetate Generic 18 $1,293
Dexamethasone Generic 14 $395
Tamoxifen Citrate Generic 15 $356
Prochlorperazine Maleate Generic 21 $276
Ondansetron Hcl Generic 18 $221
Duloxetine Hcl Generic 17 $181
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 13 $166
Pantoprazole Sodium Generic 14 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$10,035

Medicare's payments for the services billed

Medicare patients

112

Average age 72

Services billed

255

112 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Cancer 58%
Arthritis 57%
Depression 33%
Osteoporosis 28%
Diabetes 27%
Chronic kidney disease 26%
Ischemic heart disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record